Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.76 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palmitoyl-Carnitine SCHEMBL20608769 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL21569424 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL22392377 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL22206068 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL25375657 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL21114352 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL25373349 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL22392372 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL22440886 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL22440885 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220118269-A1 | MONITORING EFFICACY OF MAGNETIC AND ELECTRIC FIELDS USING BIOMARKERS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2022-04-21 | — | — | US | claimed |
| EP-3908374-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | Epitracker, Inc. (US) | 2021-11-17 | — | — | EP | claimed |
| US-20210330734-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | Epitracker, Inc. | 2021-10-28 | — | — | US | claimed |
| EP-3796976-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | Epitracker, Inc. (US) | 2021-03-31 | — | — | EP | claimed |
| WO-2020146263-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | Epitracker, Inc. (US) | 2020-07-16 | — | — | WO | claimed |
| US-20260137646-A1 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | EPITRACKER INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | EPITRACKER INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260034086-A1 | Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis | HILL'S PET NUTRITION, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | UNIV CALIFORNIA (US) | 2025-12-11 | — | — | US | disclosed |
| US-12458617-B2 | Pet food compositions comprising caprylic acid and docosahexaenoic acid and/or eicosapetaenoic acid for use in treating struvite urolithiasis | HILL'S PET NUTRITION, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-3709817-B2 | COMPOSITIONS COMPRISING OMEGA-3 POLYUNSATURATED AND MEDIUM CHAIN FATTY ACIDS | HILLS PET NUTRITION INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12427179-B2 | Compositions and methods for diagnosis and treatment of neurodegenerative diseases | Epitracker, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-3681521-A1 | METABOLOMIC REVISION OF MAMMALIAN INFANTS | Evolve Biosystems Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200225213-A1 | COMPOSITIONS AND METHODS FOR DETECTING CARDIOTOXICITY | AGEX THERAPEUTICS, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| WO-2020146263-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | Epitracker, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| US-10451641-B2 | Compositions and methods for metabolic profiling in subjects with heart failure with preserved ejection fraction | DUKE UNIVERSITY (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190310269-A1 | SYSTEMS AND METHODS FOR MEASURING OBESITY USING METABOLOME ANALYSIS | HUMAN LONGEVITY, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190156919-A1 | DETERMINING RELATIONSHIPS BETWEEN RISKS FOR BIOLOGICAL CONDITIONS AND DYNAMIC ANALYTES | ARIVALE, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| WO-2019055718-A1 | METABOLOMIC REVISION OF MAMMALIAN INFANTS | Evolve Biosystems, Inc. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20180067137-A1 | COMPOSITIONS AND METHODS FOR METABOLIC PROFILING IN SUBJECTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION | DUKE UNIVERSITY (US) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | CYP27A1, LIPC, CYP46A1 | MAPK1 3368/4885MAPT 1772/4885LMNA 2028/4885 |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | CD4, COL2A1, MMP1 | MAPK1 1053/4885MAPT 175/4885LMNA 931/4885 |
| US-20260137646-A1 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | HTR6, HTR2A, OPRL1 | MAPK1 3010/4885MAPT 197/4885LMNA 3177/4885 |
| US-20260034086-A1 | Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis | FPR2, FPR1, FPR3 | MAPK1 3434/4885MAPT 2558/4885LMNA 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.